News Release of The Howard Group's Client

09:44 EDT Thursday, May 29, 2008

MONTREAL , May 29 /CNW Telbec/ - LMS Medical Systems (TSX:LMZ), a healthcare technology company and developer of the CALM(R) patient safety software systems for obstetrics, today announced that Donald H. Bauman, Jr. has joined LMS as Vice President and General Manager of Sales and Marketing. With this addition, LMS is responding to the ever growing demand for its obstetrical offerings.

Mr. Bauman brings over 20 years of field experience to LMS. In past assignments, he has been successful in accelerating market penetration of innovative technologies that have transformed healthcare practices and increased patient safety, including enterprise clinical systems, medication management and infection prevention. He has also developed networks of complementary resources and partners to enhance the value of offerings.

"Improving obstetrical outcomes through risk reduction is gaining heightened attention with clinicians, hospitals and insurers," said Diane Côté, CEO of LMS. "As we concentrate on increasing our presence in the market, we are pleased to welcome Don to the leadership team as he brings extensive experience in the patient safety arena from previous healthcare technology sales and marketing successes."

"LMS offerings represent the next generation of technology dedicated to improving obstetrical care," said Don. "I am most excited to lead the sales and marketing team that focuses on making labor and delivery a safer experience for families and for clinicians alike."

LMS is a leader in the application of advanced mathematical modeling and neural networks for medical use. The LMS CALM Suite provides physicians, nursing staff, risk managers and hospital administrators with clinical information systems and risk management tools designed to improve outcomes and patient care for mothers and their infants during childbirth.

Except for historical information contained herein, the matters discussed in this news release are forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed implied by the forward-looking statements including, but without limitation, economic conditions in general and in the healthcare market, the demand for and market for our products in domestic and international markets, our current dependence on the CALM product suite, the challenges associated with developing new products and obtaining regulatory approvals if necessary, research and development activities, the uncertainty of acceptance of our products by the medical community, the lengthy sales cycle for our products, third party reimbursement, competition in our markets, including the potential introduction of competitive products by others, our dependence on our distributors, physician training, enforceability and the costs of enforcement of our patents, potential infringements of our patents and the other factors set forth from time to time in the Company's filings with the United States Securities and Exchange Commission and with the Canadian Securities Commissions. The Company has no intention of or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.